Abstract
Get full access to this article
View all access options for this article.
References
1.
De Napoli
G
Gotti
E
Baldovini
C
, et al . Cardiogenic shock after ocrelizumab infusion in relapsing–remitting multiple sclerosis . Mult Scler J . 2025 .
2.
Cheungpasitporn
W
Kopecky
SL
Specks
U
, et al . Non-ischemic cardiomyopathy after rituximab treatment . J Ren Inj Prev . 2016 ; 6 : 18 –25 .
3.
Hauser
SL
Kappos
L
Montalban
X
, et al . Safety of ocrelizumab in patients with relapsing and primary progressive MS . Neurology . 2021 ; 97 : e1546–e1559.
4.
Al-Yafeai
Z
Carvajal-González
A
Abduljabar
H
, et al . Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study . Int J Cardiol . 2022 ; 362 : 153 –157 .